Δημοσιεύσεις

Κατάλογος ενδεικτικών δημοσιεύσεων του τμήματος Ιατρικής ΑΠΘ σε διεθνή επιστημονικά περιοδικά κατά τα τελευταία 5 έτη.

Export 210 results:
Συντάκτης Τίτλος [ Τύπος(Desc)] Έτος
Φίλτρα: Συντάκτης is Athyros, Vasilios G  [Clear All Filters]
Journal Article
Anagnostis, P., Katsiki N., Adamidou F., Athyros V. G., Karagiannis A., Kita M., et al. (2013).  11beta-Hydroxysteroid dehydrogenase type 1 inhibitors: novel agents for the treatment of metabolic syndrome and obesity-related disorders?. Metabolism. 62(1), 21-33.
Athyros, V. G., Katsiki N., Karagiannis A., & Mikhailidis D. P. (2014).  The 2013 American College of Cardiology/American Heart Association guidelines for the treatment of dyslipidemia: mind the gaps!. Curr Med Res Opin. 30(9), 1701-5.
Katsiki, N., Athyros V. G., & Karagiannis A. (2014).  Achieving lipid targets in primary care settings.. Curr Med Res Opin. 30(10), 1971-4.
Mikhailidis, D. P., & Athyros V. G. (2014).  Acute kidney injury: Short-term statin therapy for prevention of contrast-induced AKI.. Nat Rev Nephrol. 10(1), 8-9.
Anagnostis, P., Katsiki N., Athyros V. G., & Karagiannis A. (2014).  Adiponectin and Aldosterone in Left Ventricular Hypertrophy: An Intriguing Interplay.. Angiology.
Anagnostis, P., Karagiannis A., Tziomalos K., Kakafika A. I., Athyros V. G., & Mikhailidis D. P. (2009).  Adrenal incidentaloma: a diagnostic challenge.. Hormones (Athens). 8(3), 163-84.
Athyros, V. G., Tziomalos K., Karagiannis A., Wierzbicki A. S., & Mikhailidis D. P. (2010).  Aggressive statin treatment, very low serum cholesterol levels and haemorrhagic stroke: is there an association?. Curr Opin Cardiol. 25(4), 406-10.
Katsiki, N., Mikhailidis D. P., Athyros V. G., & Karagiannis A. (2011).  Alanine aminotransferase is associated with metabolic syndrome independently of insulin resistance.. Circ J. 75(8), 2027; author reply 2028.
Mikhailidis, D. P., Katsiki N., Athyros V. G., & Karagiannis A. (2013).  Alcohol consumption and the heart.. Int J Cardiol. 168(4), 4319.
Athyros, V. G., Mikhailidis D. P., Kakafika A. I., Tziomalos K., & Karagiannis A. (2007).  Angiotensin II reactivation and aldosterone escape phenomena in renin-angiotensin-aldosterone system blockade: is oral renin inhibition the solution?. Expert Opin Pharmacother. 8(5), 529-35.
Georgianou, E., Georgianos P. I., Petidis K., Athyros V. G., Sarafidis P. A., & Karagiannis A. (2018).  Antihypertensive therapy in acute ischemic stroke: where do we stand?. J Hum Hypertens. 32(12), 799-807.
Tziomalos, K., Athyros V. G., Karagiannis A., & Mikhailidis D. P. (2009).  Anti-inflammatory effects of fibrates: an overview.. Curr Med Chem. 16(6), 676-84.
Athyros, V. G., Kakafika A. I., Tziomalos K., Karagiannis A., & Mikhailidis D. P. (2008).  Antisense technology for the prevention or the treatment of cardiovascular disease: the next blockbuster?. Expert Opin Investig Drugs. 17(7), 969-72.
Athyros, V. G., Katsiki N., Karagiannis A., & Mikhailidis D. P. (2014).  Are statins 'IDEAL' for non-alcoholic fatty liver disease?. Curr Med Res Opin. 30(2), 229-31.
Athyros, V. G., Liberopoulos E. N., Mikhailidis D. P., Papageorgiou A. A., Ganotakis E. S., Tziomalos K., et al. (2007).  Association of drinking pattern and alcohol beverage type with the prevalence of metabolic syndrome, diabetes, CHD, stroke, and peripheral arterial disease in a Mediterranean cohort.. Angiology. 58(6), 689-97.
Karagiannis, A., Mikhailidis D. P., Kakafika A. I., Tziomalos K., & Athyros V. G. (2007).  Atenolol: differences in mode of action compared with other antihypertensives. An opportunity to identify features that influence outcome?. Curr Pharm Des. 13(2), 229-39.
Stavrinou, E., Koumaras C., Gossios T. D., Tziomalos K., Athyros V. G., & Karagiannis A. (2011).  Atherosclerotic renal artery stenosis: an update on diagnosis and management.. Curr Vasc Pharmacol. 9(4), 465-70.
Karagiannis, A., Tziomalos K., Anagnostis P., Gossios T., & Athyros V. G. (2009).  Atherosclerotic renal artery stenosis: medical therapy alone or in combination with revascularization?. Angiology. 60(4), 397-402.
Athyros, V. G., Kakafika A. I., Papageorgiou A. A., Tziomalos K., Skaperdas A., Pagourelias E., et al. (2007).  Atorvastatin decreases triacylglycerol-associated risk of vascular events in coronary heart disease patients.. Lipids. 42(11), 999-1009.
Athyros, V. G., Tziomalos K., Karagiannis A., & Mikhailidis D. P. (2010).  Atorvastatin: safety and tolerability.. Expert Opin Drug Saf. 9(4), 667-74.
Katsiki, N., Athyros V. G., & Karagiannis A. (2014).  Beneficial effects of high atorvastatin dose reloading prior to percutaneous coronary intervention.. Curr Med Res Opin. 30(1), 55.
Athyros, V. G., Sachinidis A. G., Zografou I., Simoulidou E., Piperidou A., Stavropoulos N., et al. (2018).  Boosting the Limited Use of Mineralocorticoid Receptor Antagonists Through New Agents for Hyperkalemia.. Curr Pharm Des. 24(46), 5542-5547.
Stavropoulos, K., Imprialos K. P., Boutari C., Athyros V. G., & Karagiannis A. I. (2016).  Canagliflozin and Hypertension: Is It the Optimal Choice for All Hypertensive Patients?. J Clin Hypertens (Greenwich). 18(10), 1073.
Pagourelias, E. D., Koumaras C., Kakafika A. I., Tziomalos K., Zorou P. G., Athyros V. G., et al. (2009).  Cardiorenal anemia syndrome: do erythropoietin and iron therapy have a place in the treatment of heart failure?. Angiology. 60(1), 74-81.
Athyros, V. G., Tziomalos K., Katsiki N., Doumas M., Karagiannis A., & Mikhailidis D. P. (2015).  Cardiovascular risk across the histological spectrum and the clinical manifestations of non-alcoholic fatty liver disease: An update.. World J Gastroenterol. 21(22), 6820-34.

Σελίδες

Επικοινωνία

Τμήμα Ιατρικής, Πανεπιστημιούπολη ΑΠΘ, T.K. 54124, Θεσσαλονίκη
 

Συνδεθείτε

Το τμήμα Ιατρικής στα κοινωνικά δίκτυα.
Ακολουθήστε μας ή συνδεθείτε μαζί μας.

           

Σύνδεσμοι

 

Το πανεπιστήμιο

 
 

Προσωπικό & Φοιτητές